How much profit has Epizyme made this year?
Epizyme has made -163.37 M USD this year.
Epizyme Net Income 2024
Epizyme Net Income
-163.37 M USD
Ticker
EPZM
ISIN
US29428V1044
WKN
A1T9L2
In 2024, Epizyme's profit amounted to -163.37 M USD, a -17.03% increase from the -196.9 M USD profit recorded in the previous year.
The Epizyme Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2026e | - |
| 2025e | - |
| 2024e | - |
| 2023e | - |
| 2022e | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
Epizyme Revenue, EBIT, Net Income US29428V1044 · A1T9L2
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Epizyme, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Epizyme from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Epizyme’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Epizyme. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Epizyme’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Epizyme’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Epizyme’s growth potential.
Epizyme Revenue, EBIT and net profit per share
| Date | Epizyme Revenue | Epizyme EBIT | Epizyme Net Income |
|---|---|---|---|
| 2026e | 344.06 M undefined | -180.07 M undefined | -214.87 M undefined |
| 2025e | 206.31 M undefined | -167.58 M undefined | -185.51 M undefined |
| 2024e | 126.19 M undefined | -159.07 M undefined | -163.37 M undefined |
| 2023e | 74.9 M undefined | -178.68 M undefined | -196.9 M undefined |
| 2022e | 45.38 M undefined | -186 M undefined | -230.62 M undefined |
| 2021 | 37.43 M undefined | -237.99 M undefined | -251.12 M undefined |
| 2020 | 15.76 M undefined | -225.42 M undefined | -231.69 M undefined |
| 2019 | 23.8 M undefined | -177.14 M undefined | -173.24 M undefined |
| 2018 | 21.7 M undefined | -128.11 M undefined | -123.63 M undefined |
| 2017 | 10 M undefined | -136.84 M undefined | -134.31 M undefined |
| 2016 | 8.01 M undefined | -111.83 M undefined | -110.21 M undefined |
| 2015 | 2.56 M undefined | -132.55 M undefined | -132.38 M undefined |
| 2014 | 41.41 M undefined | -55.05 M undefined | -55.01 M undefined |
| 2013 | 68.48 M undefined | -3.13 M undefined | -3.75 M undefined |
| 2012 | 45.22 M undefined | -770,000 undefined | -1.19 M undefined |
| 2011 | 6.94 M undefined | -20.97 M undefined | -21 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2011 | 6.94 M USD | -20.97 M USD | -21 M USD |
| 2012 | 45.22 M USD | -770,000 USD | -1.19 M USD |
| 2013 | 68.48 M USD | -3.13 M USD | -3.75 M USD |
| 2014 | 41.41 M USD | -55.05 M USD | -55.01 M USD |
| 2015 | 2.56 M USD | -132.55 M USD | -132.38 M USD |
| 2016 | 8.01 M USD | -111.83 M USD | -110.21 M USD |
| 2017 | 10 M USD | -136.84 M USD | -134.31 M USD |
| 2018 | 21.7 M USD | -128.11 M USD | -123.63 M USD |
| 2019 | 23.8 M USD | -177.14 M USD | -173.24 M USD |
| 2020 | 15.76 M USD | -225.42 M USD | -231.69 M USD |
| 2021 | 37.43 M USD | -237.99 M USD | -251.12 M USD |
| 2022e | 45.38 M USD | -186 M USD | -230.62 M USD |
| 2023e | 74.9 M USD | -178.68 M USD | -196.9 M USD |
| 2024e | 126.19 M USD | -159.07 M USD | -163.37 M USD |
| 2025e | 206.31 M USD | -167.58 M USD | -185.51 M USD |
| 2026e | 344.06 M USD | -180.07 M USD | -214.87 M USD |
Epizyme stock margins US29428V1044 · A1T9L2
The Epizyme margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Epizyme. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Epizyme.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Epizyme's sales revenue. A higher gross margin percentage indicates that the Epizyme retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Epizyme's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Epizyme's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Epizyme's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Epizyme. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Epizyme's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Epizyme Margin History
| Epizyme Gross margin | Epizyme Profit margin | Epizyme EBIT margin | Epizyme Profit margin |
|---|---|---|---|
| 2026e | 71.95 % | -52.34 % | -62.45 % |
| 2025e | 71.95 % | -81.23 % | -89.92 % |
| 2024e | 71.95 % | -126.06 % | -129.47 % |
| 2023e | 71.95 % | -238.56 % | -262.88 % |
| 2022e | 71.95 % | -409.9 % | -508.23 % |
| 2021 | 71.95 % | -635.88 % | -670.96 % |
| 2020 | 67.89 % | -1,430.33 % | -1,470.11 % |
| 2019 | 71.95 % | -744.29 % | -727.9 % |
| 2018 | 71.95 % | -590.37 % | -569.72 % |
| 2017 | 71.95 % | -1,368.4 % | -1,343.1 % |
| 2016 | 71.95 % | -1,396.13 % | -1,375.91 % |
| 2015 | 71.95 % | -5,177.73 % | -5,171.09 % |
| 2014 | 71.95 % | -132.94 % | -132.84 % |
| 2013 | 71.95 % | -4.57 % | -5.48 % |
| 2012 | 71.95 % | -1.7 % | -2.63 % |
| 2011 | 71.95 % | -302.16 % | -302.59 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2011 | 71.95 % | -302.16 % | -302.59 % |
| 2012 | 71.95 % | -1.7 % | -2.63 % |
| 2013 | 71.95 % | -4.57 % | -5.48 % |
| 2014 | 71.95 % | -132.94 % | -132.84 % |
| 2015 | 71.95 % | -5,177.73 % | -5,171.09 % |
| 2016 | 71.95 % | -1,396.13 % | -1,375.91 % |
| 2017 | 71.95 % | -1,368.4 % | -1,343.1 % |
| 2018 | 71.95 % | -590.37 % | -569.72 % |
| 2019 | 71.95 % | -744.29 % | -727.9 % |
| 2020 | 67.89 % | -1,430.33 % | -1,470.11 % |
| 2021 | 71.95 % | -635.88 % | -670.96 % |
| 2022e | 71.95 % | -409.9 % | -508.23 % |
| 2023e | 71.95 % | -238.56 % | -262.88 % |
| 2024e | 71.95 % | -126.06 % | -129.47 % |
| 2025e | 71.95 % | -81.23 % | -89.92 % |
| 2026e | 71.95 % | -52.34 % | -62.45 % |
Epizyme Aktienanalyse
What does Epizyme do?
Epizyme Inc is an American biotechnology company specializing in the development of therapeutic products for the treatment of cancer and genetic metabolic disorders. The company was founded in 2007 in Cambridge, Massachusetts. Epizyme focuses on developing drugs that target epigenetic changes in cells, which are changes in gene expression caused by changes in DNA structure. Epizyme specializes in the development of inhibitors of histone deacetylase enzymes (HDAC), which suppress the activity of enzymes involved in cell cycle regulation, apoptosis, and DNA repair. The company is divided into different business units focusing on different therapy areas, including oncology, hematologic oncology, and genetic metabolic disorders. In the field of oncology, Epizyme develops drugs for the treatment of blood and lymphatic system cancers such as diffuse large B-cell lymphoma and T-cell lymphoma. In the field of hematologic oncology, the company develops drugs for the treatment of blood disorders like myelodysplastic syndrome and acute myeloid leukemia. In the field of genetic metabolic disorders, Epizyme develops drugs for the treatment of lysosomal storage diseases. The company's business model primarily involves developing its own therapy products and collaborating with other biopharmaceutical companies and the pharmaceutical industry. Epizyme is listed on NASDAQ under the ticker symbol EPZM and has raised over $230 million in funding. Overall, Epizyme is an innovative company with a promising pipeline of drug candidates that works closely with other industry players to achieve its goals. It has established itself as a key player in the biotechnology industry. Epizyme ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding Epizyme's Profit Margins
The profit margins of Epizyme represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Epizyme's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating Epizyme's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
Epizyme's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When Epizyme’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about Epizyme stock
How has the profit developed compared to last year?
The profit has increased by -17.03% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does Epizyme publish its earnings?
Epizyme publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of Epizyme?
The profits of Epizyme are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of Epizyme?
You can learn more about the earnings of Epizyme by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does Epizyme pay?
Over the past 12 months, Epizyme paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Epizyme is expected to pay a dividend of 0 USD.
What is the dividend yield of Epizyme?
The current dividend yield of Epizyme is .
When does Epizyme pay dividends?
Epizyme pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Epizyme?
Epizyme paid dividends every year for the past 0 years.
What is the dividend of Epizyme?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Epizyme located?
Epizyme is assigned to the 'Health' sector.
Wann musste ich die Aktien von Epizyme kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Epizyme from 11/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/17/2024.
When did Epizyme pay the last dividend?
The last dividend was paid out on 11/17/2024.
What was the dividend of Epizyme in the year 2023?
In the year 2023, Epizyme distributed 0 USD as dividends.
In which currency does Epizyme pay out the dividend?
The dividends of Epizyme are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Epizyme stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von Epizyme
Our stock analysis for Epizyme Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Epizyme Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
